Literature DB >> 7158271

Effect of labetalol on intracranial pressure in dogs with and without intracranial hypertension.

H Van Aken, C Puchstein, M L Schweppe, A Heinecke.   

Abstract

Intracranial pressure measurements and ventricular volume pressure response curves were made during induced hypotension with labetalol, a combined alpha- and beta-adrenoceptor antagonist, in dogs without (group I) and with (group II) intracranial hypertension. The administration of 600 mg labetalol resulted in a percentage decrease of mean systemic arterial blood pressure (MAP) of 27% (+/- 10%) in group I, and 32% (+/- 9%) in group II from control values without changes in intracranial pressure and the ventricular volume pressure response curve. Larger decreases in MAP were not possible, even with a dose 3 times that clinically recommended. Labetalol may be a safe hypotensive agent to supplement neurolept analgesia, but it is not the drug of choice to induce deliberate hypotension.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7158271     DOI: 10.1111/j.1399-6576.1982.tb01826.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  4 in total

Review 1.  Induced hypotension during anesthesia with special reference to orthognathic surgery.

Authors:  C Rodrigo
Journal:  Anesth Prog       Date:  1995

2.  The influence of labetalol on arterial blood gas data, pulmonary haemodynamics and pulmonary shunting.

Authors:  S G De Hert; L G Heytens; R G De Jongh; M P Vercauteren; E A Boeckx; H F Adriaensen
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

3.  A multicenter comparison of outcomes associated with intravenous nitroprusside and nicardipine treatment among patients with intracerebral hemorrhage.

Authors:  M Fareed K Suri; Gabriela Vazquez; Mustapha A Ezzeddine; Adnan I Qureshi
Journal:  Neurocrit Care       Date:  2009-02-18       Impact factor: 3.210

4.  Retrospective evaluation of labetalol as antihypertensive agent in dogs.

Authors:  Francesco Zublena; Chiara De Gennaro; Federico Corletto
Journal:  BMC Vet Res       Date:  2020-07-24       Impact factor: 2.741

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.